Drug Trial Radar · NCT06147063
A Randomized Trial Evaluating a mRNA-VLP Vaccine's Immunogenicity and Safety for COVID-19
Last checked: Nov 20, 2026Latest source record: Aug 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
243
Actual
Start
Nov 27, 2023
Primary completion
Apr 30, 2024
Study completion Mar 27, 2025
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Nov 27, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to characterize the safety and immunogenicity of AZD9838 and AZD6563 when administered as a single dose vaccination against SARS-CoV-2 in adults.
Conditions
- COVID-19
- SARS-CoV-2 Infection
Interventions
AZD9838Biological
Intramuscular (IM) injection.
Licensed SARS-CoV-2 mRNA vaccineBiological
Intramuscular (IM) injection.
AZD6563Biological
Intramuscular (IM) injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with immediate unsolicited adverse events (AE)Time frame: Within 30 minutes post vaccination
- Number of participants with injection site and systemic solicited adverse reactions (ARs)Time frame: Through 7 days post vaccination
- Number of participants with any unsolicited adverse events (AEs)Time frame: Through 28 days post vaccination
- Number of participants with serious adverse events (SAEs), Medically-attended adverse events (MAAEs), and Adverse Events of Special Interest (AESIs)Time frame: Through 12 months post vaccination
- Model-adjusted geometric mean titer (GMT) for SARS-CoV-2 ancestral strain neutralizing antibodiesTime frame: Day 29
- Model-adjusted geometric mean titer (GMT) for SARS-CoV-2 Omicron BA.4/5 neutralizing antibodiesTime frame: Day 29
- Model-adjusted geometric mean titer (GMT) for SARS-CoV-2 Omicron XBB.1.5 neutralizing antibodiesTime frame: Day 29
- Geometric mean fold rise (GMFR) for SARS-CoV-2 ancestral strain neutralizing antibodiesTime frame: Day 1 to Day 29
- Geometric mean fold rise (GMFR) for SARS-CoV-2 Omicron BA.4/5 neutralizing antibodiesTime frame: Day 1 to Day 29
- Geometric mean fold rise (GMFR) for SARS-CoV-2 Omicron XBB.1.5 neutralizing antibodiesTime frame: Day 1 to Day 29
- Proportion of participants with neutralizing antibody seroresponse against SARS-CoV-2 ancestral strainTime frame: Day 1 to Day 29
- Proportion of participants with neutralizing antibody seroresponse against SARS-CoV-2 Omicron BA.4/5Time frame: Day 1 to Day 29
- Proportion of participants with neutralizing antibody seroresponse against SARS-CoV-2 Omicron XBB.1.5Time frame: Day 1 to Day 29
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Research Site
Long Beach, California
Research Site
Rolling Hills Estates, California
Research Site
Chicago, Illinois
Research Site
Wichita, Kansas
Research Site
North Charleston, South Carolina
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.